Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease

Clinical and Experimental Rheumatology

Volumn 28, Issue 3, 2010, Pages 424-433

  Ruperto, Nicolino ^a   Bazso, A ^a   Pistorio, A ^b   Ravelli, A ^a   Filocamo, G ^a   Hernandez Huirache, H G ^a   Rodriguez Lozano, A L ^a   Pringe, A B ^a   Vilca, I ^a   Martini, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

Core set; Disease activity; Juvenile systemic lupus erythematosus; Response to therapy

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; BIOLOGICAL MARKER;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; SEX RATIO; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; URINE SEDIMENT; CLINICAL TRIAL; DRUG MONITORING; FACTUAL DATABASE; HEALTH STATUS; HOSPITALIZATION; KIDNEY; LONGITUDINAL STUDY; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STANDARD; URINE;

BIOLOGICAL MARKERS; CHILD; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DRUG MONITORING; HEALTH STATUS; HUMANS; KIDNEY; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEINURIA; QUALITY OF LIFE; REFERENCE STANDARDS; SEVERITY OF ILLNESS INDEX; URINE;

EID: 77957002526     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. ILLEI GG, YARBORO CH, KUROIWA T et al.: Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis. Rheumatology (Oxford) 2007; 46: 952-6.
2. GROOTSCHOLTEN C, BAJEMA IM, FLORQUIN S et al.: Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis. Arthritis Rheum 2007; 56: 924-37.
3. BACA V, CATALAN T, VILLASIS-KEEVER M, RAMON G, MORALES AM, RODRIGUEZ-LEYVA F: Effect of low-dose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus 2006; 15: 490-5.
4. GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
5. CHAN TM, TSE KC, TANG CS, MOK MY, LI FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-84.
6. CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.
7. ILLEI GG, AUSTIN HA, III, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57.
8. CHAN TM, LI FK, TANG CSO et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-62.
9. GOURLEY MF, AUSTIN HA, III, SCOTT D et al.: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-57.
10. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
11. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial - Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-40.
12. CLARK WF, CATTRAN DC, BALFE JW, WILLIAMS W, LINDSAY RM, LINTON AL: Chronic plasma exchange in systemic lupus erythematosus nephritis. Proc Eur Dial Transplant Assoc 1983; 20: 629-35.
13. BOUMPAS DT, AUSTIN III HA, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-5.
14. RENAL DISEASE SUBCOMMITTEE OF THE AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON SYSTEMIC LUPUS ERYTHEMATOSUS RESPONSE CRITERIA: The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006; 54: 421-32.
15. MOSCA M, BOMBARDIERI S: Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 2007; 25 (Suppl. 47): S107-S13.
16. PETRI M, KASITANON N, LEE SS et al.: Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum 2008; 58: 1784-8.
17. PETRI M, KASITANON N, SINGH S et al.: Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum 2008; 58: 1789-95.
18. RUPERTO N, MARTINI A: International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004; 16: 566-70.
19. RUPERTO N, RAVELLI A, MURRAY KJ et al.: Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 1452-9.
20. RUPERTO N, RAVELLI A, CUTTICA R et al.: The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis Rheum 2005; 52: 2854-64.
21. RUPERTO N, RAVELLI A, OLIVEIRA S et al.: The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum 2006; 55: 355-63.
22. BRUNNER HI, GLADMAN DD, IBANEZ D, UROWITZ MD, SILVERMAN ED: Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556-62.
23. TUCKER LB, URIBE AG, FERNANDEZ M et al.: Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314-22.
24. KLEIN A, CIMAZ R, QUARTIER P et al.: Causes of death in pediatric systemic lupus erythematosus. Clin Exp Rheumatol 2009; 27: 538-9.
25. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
26. GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
27. RUPERTO N, RAVELLI A, FALCINI F et al.: Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 38-41.
28. RIDER LG, GIANNINI EH, BRUNNER HI et al.: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281-90.
29. RUPERTO N, RAVELLI A, PISTORIO A et al.: The provisional Pediatric Rheumatology International Trial Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 4-13.
30. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
31. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
32. LANE C, BROWN M, DUNSMUIR W, KELLY J, MANGOS G: Can spot urine protein/creatinine ratio replace 24 h urine protein in usual clinical nephrology? Nephrology (Carlton) 2006; 11: 245-9.
33. LEUNG YY, SZETO CC, TAM LS et al.: Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Rheumatology (Oxford) 2007; 46: 649-52.
34. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
35. LIANG MH, SOCHER SA, LARSON MG, SCHUR PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
36. VITALI C, BENCIVELLI W, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992; 10: 541-7.
37. VITALI C, BENCIVELLI W, MOSCA M, CARRAI P, SERENI M, BOMBARDIERI S: Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 1999; 26: 498-501.
38. BRUNNER HI, FELDMAN BM, BOMBARDIER C, SILVERMAN ED: Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum 1999; 42: 1354-60.
39. th Report): 555-76.
40. LEVEY AS, CORESH J, BALK E et al.: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
41. RUPERTO N, RAVELLI A, PISTORIO A et al.: Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001; 19: S1-S9.
42. LANDGRAF JM, ABETZ L, WARE JE: The CHQ User's Manual. First Edition. ed., Boston, MA, USA, The Health Institute, New England Medical Center, 1996.
43. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-6.
44. LIANG MH, FOSSEL AH, LARSON MG: Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990; 28: 632-42.
45. MOSTELLER F, TUKEY JW: Data analysis and regression. Reading, MA ed., Addison Wesley, 1977: 133.
46. LIANG MH, LARSON MG, CULLEN KE, SCHWARTZ JA: Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985; 28: 542-7.
47. LIANG MH: Evaluating measurement responsiveness. J Rheumatol 1995; 22: 1191-2.
48. COHEN J: A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 37-46.
49. COHEN J: Statistical Power Analysis for the Behavioral Sciences. New York, Academic Press, 1977.
50. LANDIS JR, KOCH GC: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
51. AUSTIN HA, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
52. YEE CS, GORDON C, DOSTAL C et al.: EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004; 63: 525-9.
53. WEENING JJ, D'AGATI VD, SCHWARTZ MM et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30.
54. BOUMPAS DT, BALOW JE: Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998; 7: 622-9.
55. UROWITZ MB, IBANEZ D, ALI Y, GLADMAN DD: Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. J Rheumatol 2007; 34: 1491-6.